1800 Bridge Parkway
About Nevro Corp
Nevro is a medical device company and creator of HF10™, an innovative, evidence-based treatment for chronic pain. The company, based in Redwood City, California has a simple goal of helping more patients suffering from chronic pain achieve lasting relief.
While traditional spinal cord stimulation (SCS) has been around for over 30 years, HF10™ created a disruption by offering a next-generation approach that provides patients with substantially better long-term outcomes.
HF10™ has been available in Europe and Australia since 2011 and received FDA approval in the United States in 2015. Uniquely, the FDA designated HF10 as superior to traditional SCS for the treatment of back and leg pain. Worldwide, tens of thousands of patients are enjoying more freedom and improvement in their daily lives with HF10 ™.
Please click here for job opportunities at Nevro.
Nevro: Chronic Pain Relief - HF10 Therapy Overview
An animation that explains the basics of spinal cord stimulation (SCS), how it works to provide relief from chronic back and leg pain, and how Nevro’s paresthesia-free HF10 therapy differs from traditional SCS therapies.
94 articles with Nevro Corp
NEVRO SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Nevro Corp. - NVRO
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 22, 2018 to file lead plaintiff applications in a securities class action lawsuit against Nevro Corp.
Nevro Corp. today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
Nevro Corp. reported financial results for the three and six months ended June 30, 2018.
Parties File to Dismiss Remaining Claims - Boston Scientific Represents It Has No Plans to Launch High Frequency Product
Summary Judgment Ruling Affirms Method Claims Covering 1.5kHz to 100kHz Frequency Range
Nevro to Host Conference Call on Thursday, August 2, 2018 at 1:30 p.m. PT / 4:30 p.m. ET
Nevro Announces Preliminary Unaudited Second Quarter 2018 Revenue and Updates Full Year 2018 Revenue Guidance
Company to Host Conference Call Today, Monday, July 16, 2018 at 5:30 a.m. PT / 8:30 a.m. ET
Nevro to Announce Preliminary Second Quarter Worldwide Revenue, Discuss Full Year 2018 Revenue Guidance and Provide Business Updates
Company to Host Conference Call on Monday, July 16, 2018 at 5:30 a.m. PT / 8:30 a.m. ET
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2018.
Nevro Corp. announced that its management will be presenting at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 in Las Vegas.
Every year for the last 32 years, Enrst & Young has awarded entrepreneurs in various categories, including Life Science, Consumer Products and Retail, Distribution and Manufacturing and other categories. The awards are given in June. The finalists have been announced. Here’s a look at some of the...
Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza® Spinal Cord Stimulation System
Expanding Patient Access to Nevro's HF10® Therapy Through Broader Imaging Compatibility
Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website.
Nevro to Highlight Body of Clinical Evidence Supporting Expanded Use and Potential New Indications of Company's Senza Spinal Cord Stimulation Systems Delivering HF10 Therapy at NANS Annual Meeting
Nevro Corp today announced a series of data presentations supporting the use of HF10 therapy for patients with chronic pain at the 21st Annual Meeting of the NANS taking place through January 14 in Las Vegas.
The Senza II system offers the superior outcomes and clinical advantages of HF10 therapy through a smaller and more refined footprint while maintaining the performance and durability of the current IPG.
The company announced that preliminary unaudited fourth quarter worldwide revenue is expected to be in the range of $97.4 to $97.9M.
This approval is retroactive, meaning that the new labeling for expanded imaging applies to all patients currently implanted with the Senza SCS System with percutaneous leads.
Revenue for the three months ended September 30, 2017 was $82.3M versus $60.9M during the same period of the prior year, representing 35% growth as reported.
Nevro today announced that it will release financial results for the third quarter of 2017 after market close on Monday, November 6, 2017.